Ad scientiam
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ad scientiam sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Ad scientiam: 5 sponsored US clinical trials, 2 recruiting.
Ad scientiam sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Multiple Sclerosis, with 2 trials.
Upper-quartile sponsor footprint
Ad scientiam sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
NCT05564936
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769
MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience
NCT06922942
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
NCT05816122
Descriptive Analysis of Real-world Data Collected with ME&MGopen
NCT05566964
Therapeutic Areas
What is open in the Ad scientiam pipeline
2 recruiting of 5 indexed (40% open); 1 completed (20%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Multiple Sclerosis (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ad scientiam: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Ad scientiam sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
- C4 Therapeutics · 40% recruiting · 5 trials
Related
What to do with this Ad scientiam page
5 registered trials is a research-attention snapshot, not an endorsement of Ad scientiam or any single study.
- 2 of Ad scientiam's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition Ad scientiam studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ad scientiam pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.